Clinical Trial Update: Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) [Phase 2]

View source ↗

Summary

ALPINE 4, a Phase 2 study of Aldafermin (NGM282) in subjects with compensated cirrhosis and nonalcoholic steatohepatitis, has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Aldafermin (NGM282) (Aldafermin)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Compensated Cirrhosis, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2025-03-26